Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease

Abstract Purpose Besides the well-established efficacy in preventing severe COVID-19, the impact of early treatments, namely antivirals and monoclonal antibodies (mAbs), on the time length to negativization of SARS-CoV-2 nasal swabs is still unclear. The aim of this study was to compare the efficacy...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Marta Colaneri, Giovanni Scaglione, Federico Fassio, Lucia Galli, Alessia Lai, Annalisa Bergna, Arianna Gabrieli, Maciej Tarkowski, Carla Della Ventura, Valeria Colombo, Laura Cordier, Davide Bernasconi, Mario Corbellino, Gianfranco Dedivitiis, Silvia Borghetti, Debora Visigalli, Salvatore Sollima, Giacomo Casalini, Giuliano Rizzardini, Andrea Gori, Spinello Antinori, Agostino Riva, Monica Schiavini
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2024-03-01
Colecção:	Virology Journal
Assuntos:	COVID-19 Monoclonal antibodies Time to negativization Immunosuppression Nirmatrelvir/Ritonavir
Acesso em linha:	https://doi.org/10.1186/s12985-024-02333-x
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!